Lantheus Holdings, Inc.LNTH

NasdaqHealthcareIn Vitro & In Vivo Diagnostic Substances
Price (close)
$99.72
Market cap
$6.5B
P/E
23.6x
Revenue (TTM)
$1.6B
Net income
$275.3M
Dividend yield
—
1-year total return
93.7%
Net margin
17.7%
Revenue growth
2.3%
Debt / equity
0.44x

What Lantheus Holdings, Inc. does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$339.4M$425.2M$935.1M$1.3B$1.5B$1.5B
Net income-$13.5M-$71.3M$28.1M$326.7M$312.4M$233.6M
Free cash flow$16.4M$53.9M$21.8M$259.9M$493.1M$354.1M

More on LNTH.

Figures from Lantheus Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.